Can the hair-loss drug finasteride affect mental health?

Prof Nial Wheate

writer

Prof Nial Wheate

Professor, School of Natural Sciences, Macquarie University

Jasmine Lee

writer

Jasmine Lee

For many men the gradual thinning of hair is about more than just their appearance. Finasteride, a drug widely prescribed for the treatment of male pattern baldness has been used effectively for many years for this deeply personal problem.

Yet, behind its use are growing concerns about its link to the development of depression, anxiety, and even suicidal thoughts.

There is now critical discussion among both users and health-care professionals about the potential hazards associated with its continued use.

So how does the drug work? And what does the evidence say about the risk of developing a mental health problem?

How does finasteride work?

Finasteride is used to treat androgenetic alopecia, also known as male pattern baldness. It works to regrow hair and prevent the further loss of hair.

One of the key causes of pattern baldness is the production of a hormone called dihydrotestosterone which the body makes from testosterone. When it binds to the follicles of hairs, it initiates a process called hair follicle miniaturisation. This is where the growth cycle of the hair becomes progressively shorter, resulting in thinner and weaker hair.

Finasteride works by blocking the enzyme that converts testosterone to dihydrotestosterone. By blocking the enzyme, dihydrotestosterone concentrations can be reduced by around 60–70% for the majority of men.

Finasteride was first approved in the late 1990s as a prescription-only medicine and is taken as a daily 1 milligram oral tablet. Medications available at a higher 5 mg daily dose are not used for baldness, but as a treatment for non-cancerous prostate enlargement.

This medication is not indicated for women, even though they can also have this type of hair loss.

How can it impact mental health?

Changes in mental health are not listed as an established side effect in Australian guidance given to health-care professionals.

Based on clinical trials, the most common effects include:

  • decreased libido
  • erectile dysfunction
  • reduced semen production.

The guidance also describes an increased risk of prostate cancer and a potential risk for breast cancer. Yes, men can get breast cancer too.

While initial clinical trials conducted to obtain approval for the drug didn’t demonstrate mental health concerns, monitoring of patients using the drug has since indicated a potential increased risk of depression and suicidal thoughts. But as this is based on patients self-reporting symptoms, according to the guidance there is no definitive link.

However, in May 2025, the European Medicines Agency safety committee stated suicidal thoughts was a confirmed side effect of finasteride. The European Union also advises patients that finasteride can cause a depressed mood and depression.

Similarly, in a warning about compounded finasteride, the United States Food and Drug Administration stated in April 2025 that topical formulations of the drug has similar side effects to the oral version. These include depression, anxiety and suicidal thoughts.

Options for people who are concerned the drug may be impacting their mental health?

Patients with mild symptoms may pause finasteride to see whether things improve, or try continuing with additional mental health support. If symptoms are more severe, stopping the medication and getting prompt medical review may be appropriate.

For those taking the drug who are concerned about side effects, it is safe to stop immediately. Most side effects ease once the medication is out of their system, although a small number of people have reported symptoms that persist.

When someone stops the drug, their hormone levels will gradually return to baseline and the hair growth seen with the drug will be lost over time.

If finasteride is not the right fit, there is another evidence-based alternative.

Topical minoxidil is a first-line treatment that can be used on its own or with other treatments and is available from pharmacies over the counter. It only works while it’s being used and may irritate the scalp, but its effectiveness is well-established and widely recommended.

While depression and anxiety are associated with minoxidil, the incidence is much lower because of their topical application.

There is also a medication called dutasteride. However, as it works in a similar way to finasteride, it may also increase the risk of developing mental health problems. So it is best to avoid dutasteride if finasteride is not suitable.


If this story has raised any issues for you, please contact one of the services below:

Nial Wheate, Professor, School of Natural Sciences, Macquarie University and Jasmine Lee, Pharmacist and PhD Candidate, University of Sydney

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Ron Dick

A/Prof Ron Dick

Why is LDL control important?

Prof Carol Wham

Prof Carol Wham

Malnutrition and frailty in older adults - The importance of screening and early intervention

Prof Andrew Sindone

Prof Andrew Sindone

Heart failure and obesity - Which do we manage first?

Brett Lee

Brett Lee

The social media ban - Practical preparation for children and family

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Prof Nial Wheate

writer

Prof Nial Wheate

Professor, School of Natural Sciences, Macquarie University

Jasmine Lee

writer

Jasmine Lee

Test your knowledge

Recent articles

Latest GP poll

The government told the public that the average GP is earning $280k per year. Do you think this figure is:

Very overestimated

0%

Moderately/slightly overestimated

0%

Quite accurate

0%

Moderately/slightly underestimated

0%

Very underestimated

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Final Healthed Webcast for this year!

Malnutrition and frailty in older adults - The importance of screening and early intervention

Tuesday 25th November, 7pm - 9pm AEDT

Speaker

Prof Carol Wham

Dietitian; Professor Emerita of Public Health Nutrition at Massey University, New Zealand

We invite you to our final webcast of 2025, where Prof Carol Wham will speak on frailty and malnutrition in older adults. Earn up to 4 hours CPD. RACGP & ACRRM accredited.